Nocturia in Parkinson's Disease: Why Does It Occur and How to Manage?

被引:31
|
作者
Batla, Amit [1 ]
Phe, Veronique [2 ,3 ,4 ]
De Min, Lorenzo [2 ,3 ]
Panicker, Jalesh N. [2 ,3 ]
机构
[1] UCL Inst Neurol, Dept Motor Neurosci & Movement Disorders, 7 Queen Sq, London WC1N 3BG, England
[2] Natl Hosp Neurol & Neurosurg, Dept Uroneurol, London, England
[3] UCL Inst Neurol, London, England
[4] Univ Paris 06, Pitie Salpetriere Acad Hosp, AP HP, Pierre & Marie Curie Med Sch,Dept Urol, Paris, France
来源
MOVEMENT DISORDERS CLINICAL PRACTICE | 2016年 / 3卷 / 05期
关键词
nocturia; Parkinson's disease; uro-neurology;
D O I
10.1002/mdc3.12374
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BackgroundNocturia is one of the commonest nonmotor symptoms in Parkinson's disease (PD) and has a significant impact on quality of life both for patients and their carers. There exists a relation between nocturia and poor sleep quality, falls, and institutionalization. Nocturia may manifest as a result of reduced functional bladder capacity or nocturnal polyuria; however, most often the cause is multifactorial. Disorders of circadian rhythm regulation are known to occur with sleep disturbances in PD may also contribute to nocturia. Methods and ResultsIn this review, an overview of the assessment and management of nocturia in patients with PD is presented. History taking, medication review, and a bladder diary form the cornerstone of the evaluation. Urinalysis, ultrasonography, and urodynamic studies help to assess the cause for lower urinary tract symptoms and exclude concomitant pathologies, such as bladder outlet obstruction. Antimuscarinic medications are the first-line treatment for the overactive bladder; however, caution is needed when using these medications in individuals predisposed to cognitive impairment. Desmopressin is effective for managing nocturnal polyuria. ConclusionsAn individualized approach is recommended to optimize the management of nocturia in PD.
引用
收藏
页码:443 / 451
页数:9
相关论文
共 50 条
  • [31] How much does dardarin contribute to Parkinson's disease?
    Brice, A
    LANCET, 2005, 365 (9457): : 363 - 364
  • [32] WHY DOES PHLEBOTHROMBOSIS OCCUR
    DOWNIE, VJ
    LANCET, 1951, 261 (DEC22): : 1180 - 1182
  • [33] Photosynthesis: Why does it occur?
    MacDonald, JJ
    JOURNAL OF CHEMICAL EDUCATION, 1995, 72 (12) : 1113 - 1114
  • [34] The why and how of the SynNerGe criteria of Parkinson<acute accent>s disease
    Hoglinger, Guenter U.
    Lang, Anthony E.
    JOURNAL OF NEURAL TRANSMISSION, 2024, 131 (10) : 1149 - 1154
  • [35] Initiation of pharmacological therapy in Parkinson's disease: when, why, and how
    de Bie, Rob M. A.
    Clarke, Carl E.
    Espay, Alberto J.
    Fox, Susan H.
    Lang, Anthony E.
    LANCET NEUROLOGY, 2020, 19 (05): : 452 - 461
  • [36] Endotoxin shock-associated hypothermia - How and why does it occur?
    Romanovsky, AA
    Shido, O
    Sakurada, S
    Sugimoto, N
    Nagasaka, T
    THERMOREGULATION: TENTH INTERNATIONAL SYMPOSIUM ON THE PHARMACOLOGY OF THERMOREGULATION, 1997, 813 : 733 - 737
  • [37] Infection Following Strabismus Surgery; Why Does it Occur and and How to Prevent it?
    Suh, Donny
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
  • [38] Apoptosis in cardiac disease - What is it - How does it occur
    Neuss, M
    Crow, MT
    Chesley, A
    Lakatta, EG
    CARDIOVASCULAR DRUGS AND THERAPY, 2001, 15 (06) : 507 - 523
  • [39] Apoptosis in Cardiac Disease—What is it—How Does it Occur
    Michael Neuss
    Michael T. Crow
    Alan Chesley
    Edward G. Lakatta
    Cardiovascular Drugs and Therapy, 2001, 15 : 507 - 523
  • [40] Nocturnal polyuria in patients with Parkinson's disease reporting nocturia
    Batla, A.
    Smith, M.
    Seth, J.
    Hofereiter, J.
    Bhatia, K. P.
    Panicker, J. N.
    MOVEMENT DISORDERS, 2014, 29 : S559 - S560